The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model

Background: The farnesoid X receptor (FXR) influences hepatic metabolism, inflammation and liver fibrosis as key components of non-alcoholic steatohepatitis (NASH). We studied the effects of the non-steroidal FXR agonist cilofexor (formerly GS-9674) on portal pressure and fibrosis in experimental NA...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Biomedicines
Autors principals: Schwabl, Philipp, Hambruch, Eva, Budas, Grant R., Supper, Paul, Burnet, Michael, Liles, John T., Birkel, Manfred, Brusilovskaya, Ksenia, Königshofer, Philipp, Peck-Radosavljevic, Markus, Watkins, William J., Trauner, Michael, Breckenridge, David G., Kremoser, Claus, Reiberger, Thomas
Format: Artigo
Idioma:Inglês
Publicat: MDPI 2021
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7827357/
https://ncbi.nlm.nih.gov/pubmed/33435509
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/biomedicines9010060
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars